We would love to hear your thoughts about our site and services, please take our survey here.
Because
For about 7 -10 day s you can only buy £2,000 or so and then once bought it often goes to negotiates trade to buy , this is counter intuitive for a marker maker who wants to make a "market "
So now it's moved to 1.6p ask price it will soon be hard to buy after 1 or 2 buys
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells.
Thanks NK
Pyc are at the forefront of huge change in drug approval amd testing using A.I and mathematics
They ar e due to hit £900k+revenues and a pipeline of £1.6mln (up 60% in 4mths )
PYC current valuation is ludicrous
Be interesting to see if he clears his name, in the shirt time I've seen SRT mentioned he seems to over promise and under deliver
This almost describes perfectly PYC target market
With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer drug helps to maximise DNA damage and selectively kill cancer cells. This provides a targeted approach to cancer treatment with the potential to improve patient outcomes across multiple tumour types.
Interesting developments at fellow bio tech AGL
Could well be PYC next to form this type of partnership? (Alongsode our work with merck)
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR